遺伝子編集市場：製品・サービス別（試薬、消耗品、システム、ソフトウェア）、技術別（CRISPR、TALEN、ZFN、アンチセンス）、用途別（細胞株工学、遺伝子工学、創薬）、エンドユーザー別（製薬、バイオテクノロジー） 2028年までの世界予測

Gene Editing Market by Product & Service (Reagents, Consumables, Systems, Software), Technology (CRISPR, TALEN, ZFN, Antisense), Application (Cell Line Engineering, Genetic Engineering, Drug Discovery), End User (Pharma, Biotech) Global Forecast to 2028

遺伝子編集市場は、CAGR15.0%で2023年の53億米ドルから2028年には106億米ドルに成長すると予測されている。政府資金の増加とゲノミクス・プロジェクト数の増加が、市場にとってインパクトの大きい推進要因として... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年7月14日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	209	257	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

遺伝子編集市場は、CAGR15.0%で2023年の53億米ドルから2028年には106億米ドルに成長すると予測されている。政府資金の増加とゲノミクス・プロジェクト数の増加が、市場にとってインパクトの大きい推進要因として浮上している。2022年3月、米国国立衛生研究所（NIH）は遺伝子編集研究への資金提供を拡大し、追加プロジェクトに8900万米ドルを割り当てた。同様に、欧州連合（EU）はHorizon 2020プログラムを立ち上げ、ゲノム研究と遺伝子編集プロジェクトを促進するために多額の財源を提供している。さらに、中国、日本、韓国を含むいくつかの国は、遺伝子編集技術の進歩を推進するために、国家ゲノムプログラムを設立し、専用の資金を提供している。

"予測期間中、遺伝子編集サービスが最も高い成長を目撃する"
製品・サービスに基づいて、遺伝子編集市場は試薬・消耗品、ソフトウェア・システム、サービスに区分される。遺伝子編集サービス市場には、シーケンスサービス、データ解析、バイオインフォマティクスサービス、およびインフォマティクス、クリーンアップ、遺伝子発現、DNA合成サービスなどのその他のサービスが含まれる。さらに、サービスプロバイダーはカスタマイズされたシーケンスサービスも提供している。生物医学アプリケーションにおけるシーケンスサービスの導入は、ゲノムシーケンスの需要を高め、遺伝子編集市場を後押しすると予想される。
"製薬・バイオテクノロジー企業が2022年の世界遺伝子編集市場で最大シェアを占める"
エンドユーザーに基づき、遺伝子編集市場は製薬＆バイオテクノロジー企業、学術＆研究機関、その他のエンドユーザーに区分される。その他のエンドユーザーには、診断会社、CRO、CDMOが含まれる。ファーマコゲノミクスなどの製薬アプリケーションにおける遺伝子編集の高い需要が、予測期間を通じてこのセグメントの優位性に寄与している。バイオマーカーの重要性の高まりは、医薬品開発におけるバイオマーカーの様々な応用に起因して、このセグメントにおけるゲノムシステムおよびサービスの利用を促進すると予想される。これに伴い、バイオテクノロジー企業も新しい治療薬を発見・開発するためにゲノムデータベースを構築している。

「アジア太平洋地域は予測期間中に最も高いCAGRを記録すると推定されている。
遺伝子編集市場は、北米、欧州、アジア太平洋（APAC）、中南米、中東・アフリカ（MEA）に区分される。アジア太平洋地域は、研究への投資の増加や、生物の細胞や組織の遺伝子工学のための遺伝子合成の用途が増加していることから、遺伝子編集の市場が最も急成長すると予想される。がんは日本における主要な死因のひとつとなっており、政府はその有病率と死亡率を減少させるためにさまざまな取り組みを行っている。例えば、医療研究開発機構は、日本再生医療プロジェクト、日本ゲノム医療プロジェクト、日本がん研究プロジェクトなど、多くの研究プロジェクトを実施している。また、日本市場では、技術的に先進的な製品やサービスを導入・提供しようとする地元組織と大手グローバル企業との間で、さまざまな協力や提携が行われている。
供給側の一次インタビューの内訳、企業タイプ別、呼称別、地域別：

- 回答者別供給側（70％）、需要側（30）
- 役職別Cレベル(55%)、ディレクターレベル(20%)、その他(25%)
- 地域別北米(50%)、欧州(20%)、アジア太平洋地域(20%)、その他地域(10%)

レポート掲載企業一覧
- Merck KGaA (ドイツ)
- サーモフィッシャーサイエンティフィック（米国）
- ジェンスクリプト（中国）
- アジレント・テクノロジー（米国）
- パーキンエルマー（米国）
- ロンザ（スイス）
- テカンライフサイエンス（スイス）
- サンガモ・セラピューティクス（米国）
- エディタス・メディシン（米）
- CRISPR Therapeutics AG （スイス）
- プレシジョン・バイオサイエンシズ（米国）
- Cellectis S.A.（フランス）
- インテリア・セラピューティクス（米）
- ブルーバード・バイオ（米）
- リジェネロン・ファーマシューティカルズ（米）
- AMSBIO（イギリス）
- クリエイティブ・バイオジーン（米）
- シンセゴ・コーポレーション（米）
- ビーム・セラピューティクス（米）
- カリブー・バイオサイエンシズ（米）
- オリジーン・テクノロジーズ（米）
- ニューイングランドバイオラボ（米）
- インスクリプタ（米）
- マンモス・バイオサイエンシズ（米）

調査範囲
この調査レポートは、遺伝子編集市場を製品＆サービス、技術、用途、エンドユーザー、地域に基づいて調査しています。また、市場成長に影響を与える要因（促進要因、阻害要因、機会、課題など）を分析しています。利害関係者向けに市場の機会と課題を評価し、市場リーダー向けに競争状況の詳細を提供しています。また、マイクロ市場についても、その成長動向、展望、遺伝子編集市場全体への貢献に関して調査しています。主要5地域に関して市場セグメントの収益を予測しています。

レポートを購入する理由
本レポートは、以下のポイントに関する洞察を提供する：

- 市場への浸透：市場上位25社が提供する遺伝子編集に関する包括的な情報。遺伝子編集市場を製品・サービス、技術、用途、エンドユーザー、地域別に分析しています。
- 市場開発：有利な新興市場に関する包括的情報。主要地域にわたる様々な製品/サービス/技術の市場を分析しています。
- 市場の多様化：遺伝子編集市場における未開拓の地域、最近の開発、投資に関する網羅的な情報。
- 競合評価：遺伝子編集市場における主要企業の市場シェアと戦略を詳細に評価

ページTOPに戻る

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS & EXCLUSIONS 30
1.3 MARKET SCOPE 31
1.3.1 MARKETS COVERED 31
1.4 YEARS CONSIDERED 31
1.5 CURRENCY CONSIDERED 32
1.6 LIMITATIONS 32
1.7 STAKEHOLDERS 32
1.8 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
FIGURE 1 RESEARCH DESIGN 34
2.1.1 SECONDARY DATA 35
2.1.2 PRIMARY DATA 35
FIGURE 2 BREAKDOWN OF PRIMARIES: GENE EDITING MARKET 36
2.2 MARKET ESTIMATION METHODOLOGY 37
FIGURE 3 GENE EDITING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 37
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022 38
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 39
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 39
2.3 MARKET GROWTH RATE PROJECTIONS 40
FIGURE 6 GENE EDITING MARKET (SUPPLY-SIDE): CAGR PROJECTIONS 41
FIGURE 7 GENE EDITING MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS 41
2.4 DATA TRIANGULATION 42
FIGURE 8 DATA TRIANGULATION METHODOLOGY 42
2.5 RESEARCH ASSUMPTIONS 43
2.6 RISK ANALYSIS 43
2.7 RECESSION IMPACT ANALYSIS 43
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 44
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 44
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 44

3 EXECUTIVE SUMMARY 45
FIGURE 9 GENE EDITING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 45
FIGURE 10 GENE EDITING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 46
FIGURE 11 GENE EDITING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 46
FIGURE 12 GENE EDITING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 47
FIGURE 13 GEOGRAPHICAL SNAPSHOT: GENE EDITING MARKET, 2022 48
4 PREMIUM INSIGHTS 49
4.1 GENE EDITING MARKET OVERVIEW 49
FIGURE 14 GROWING INVESTMENTS IN GENOMICS RESEARCH TO DRIVE MARKET GROWTH 49
4.2 NORTH AMERICA: GENE EDITING MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022) 50
FIGURE 15 REAGENTS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 50
4.3 NORTH AMERICA GENE EDITING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 50
FIGURE 16 CELL LINE ENGINEERING TO DOMINATE NORTH AMERICAN MARKET 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 17 MARKET DYNAMICS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
TABLE 4 GENOME EDITING MARKET: IMPACT ANALYSIS 52
5.2.1 DRIVERS 52
5.2.1.1 Rising government funding and number of genomics projects 52
5.2.1.2 Growing applications of genomics 53
5.2.1.3 Introduction of CRISPR-Cas9 54
5.2.2 RESTRAINTS 54
5.2.2.1 Off-target effects of CRISPR technology 54
5.2.3 OPPORTUNITIES 55
5.2.3.1 Extensive use of genome editing in personalized medicine 55
5.2.3.2 Expanding pipeline for gene therapy 55
5.2.4 CHALLENGES 56
5.2.4.1 High equipment costs 56
5.3 TECHNOLOGY ANALYSIS 56
5.4 SUPPLY AND VALUE CHAIN ANALYSIS 58
5.4.1 GENE EDITING MARKET: SUPPLY CHAIN ANALYSIS 58
FIGURE 18 GENE EDITING MARKET: SUPPLY CHAIN ANALYSIS 58
5.4.2 VALUE CHAIN ANALYSIS 59
FIGURE 19 GENE EDITING MARKET: VALUE CHAIN ANALYSIS 59

5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 60
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 60
5.6 PRICING ANALYSIS 61
TABLE 5 AVERAGE SELLING PRICES, BY PRODUCT (KEY PLAYER OFFERINGS) 61
5.7 REGULATORY ANALYSIS 62
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65
TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
5.8 ECOSYSTEM ANALYSIS 66
FIGURE 21 GENE EDITING MARKET: ECOSYSTEM ANALYSIS 66
5.9 PORTER’S FIVE FORCES ANALYSIS 67
TABLE 11 GENE EDITING MARKET: PORTER’S FIVE FORCES ANALYSIS 67
5.9.1 THREAT OF NEW ENTRANTS 67
5.9.2 THREAT OF SUBSTITUTES 67
5.9.3 BARGAINING POWER OF BUYERS 67
5.9.4 BARGAINING POWER OF SUPPLIERS 68
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 68
5.10 KEY CONFERENCES AND EVENTS IN 2023 68
TABLE 12 GENE EDITING MARKET: CONFERENCES AND EVENTS (2023) 68
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 69
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 69
FIGURE 22 GENE EDITING MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 69
5.11.2 GENE EDITING MARKET: BUYING CRITERIA 69
FIGURE 23 KEY BUYING CRITERIA FOR GENE EDITING 69
5.12 PATENT ANALYSIS 70
FIGURE 24 PATENTS GRANTED, JANUARY 2011–JUNE 2023 70
FIGURE 25 TOP PATENT APPLICANTS, JANUARY 2011–JUNE 2023 70
6 GENE EDITING MARKET, BY PRODUCT & SERVICE 71
6.1 INTRODUCTION 72
TABLE 13 GENE EDITING MARKET, BY PRODUCT & SERVICE,
2021–2028 (USD MILLION) 72
6.2 REAGENTS & CONSUMABLES 72
6.2.1 REAGENTS & CONSUMABLES TO HOLD LARGEST MARKET SHARE 72
TABLE 14 GENE EDITING REAGENTS & CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION) 73
TABLE 15 NORTH AMERICA: GENE EDITING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 16 EUROPE: GENE EDITING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 17 ASIA PACIFIC: GENE EDITING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 74
TABLE 18 LATIN AMERICA: GENE EDITING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 74
6.3 SOFTWARE & SYSTEMS 74
6.3.1 INCREASING APPLICATIONS OF GENOME EDITING/SEQUENCING TO BOOST DEMAND FOR SYSTEMS AND SOFTWARE 74
TABLE 19 GENE EDITING SOFTWARE & SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION) 75
TABLE 20 NORTH AMERICA: GENE EDITING SOFTWARE & SYSTEMS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 21 EUROPE: GENE EDITING SOFTWARE & SYSTEMS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 76
TABLE 22 ASIA PACIFIC: GENE EDITING SOFTWARE & SYSTEMS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 76
TABLE 23 LATIN AMERICA: GENE EDITING SOFTWARE & SYSTEMS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 76
6.4 SERVICES 77
6.4.1 RISING DEMAND FOR SERVICES TO SUPPORT GROWTH 77
TABLE 24 GENE EDITING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 77
TABLE 25 NORTH AMERICA: GENE EDITING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 26 EUROPE: GENE EDITING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 27 ASIA PACIFIC: GENE EDITING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 28 LATIN AMERICA: GENE EDITING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
7 GENE EDITING MARKET, BY TECHNOLOGY 79
7.1 INTRODUCTION 80
TABLE 29 GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 80
7.2 CRISPR 80
7.2.1 EASE OF USE TO BOOST DEMAND OVER OTHER TECHNOLOGIES 80
TABLE 30 GENE EDITING MARKET FOR CRISPR, BY REGION, 2021–2028 (USD MILLION) 81
TABLE 31 NORTH AMERICA: GENE EDITING MARKET FOR CRISPR, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 32 EUROPE: GENE EDITING MARKET FOR CRISPR, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 33 ASIA PACIFIC: GENE EDITING MARKET FOR CRISPR, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 34 LATIN AMERICA: GENE EDITING MARKET FOR CRISPR, BY COUNTRY, 2021–2028 (USD MILLION) 82
7.3 TALEN 82
7.3.1 ABILITY TO MAKE QUICK MODIFICATIONS TO DRIVE USAGE 82
TABLE 35 GENE EDITING MARKET FOR TALEN, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 36 NORTH AMERICA: GENE EDITING MARKET FOR TALEN, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 37 EUROPE: GENE EDITING MARKET FOR TALEN, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 38 ASIA PACIFIC: GENE EDITING MARKET FOR TALEN, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 39 LATIN AMERICA: GENE EDITING MARKET FOR TALEN, BY COUNTRY, 2021–2028 (USD MILLION) 84
7.4 ZFN 84
7.4.1 UTILITY IN EUKARYOTE CELL STUDIES TO DRIVE MARKET GROWTH 84
TABLE 40 GENE EDITING MARKET FOR ZFN, BY REGION, 2021–2028 (USD MILLION) 85
TABLE 41 NORTH AMERICA: GENE EDITING MARKET FOR ZFN, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 42 EUROPE: GENE EDITING MARKET FOR ZFN, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 43 ASIA PACIFIC: GENE EDITING MARKET FOR ZFN, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 44 LATIN AMERICA: GENE EDITING MARKET FOR ZFN, BY COUNTRY, 2021–2028 (USD MILLION) 86
7.5 ANTISENSE 86
7.5.1 INCREASED APPLICATION IN ENGINEERING HUMAN CELLS FOR DISEASE STUDY TO DRIVE MARKET GROWTH 86
TABLE 45 GENE EDITING MARKET FOR ANTISENSE, BY REGION, 2021–2028 (USD MILLION) 87
TABLE 46 NORTH AMERICA: GENE EDITING MARKET FOR ANTISENSE, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 47 EUROPE: GENE EDITING MARKET FOR ANTISENSE, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 48 ASIA PACIFIC: GENE EDITING MARKET FOR ANTISENSE, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 49 LATIN AMERICA: GENE EDITING MARKET FOR ANTISENSE, BY COUNTRY, 2021–2028 (USD MILLION) 88
7.6 OTHER TECHNOLOGIES 88
TABLE 50 GENE EDITING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 51 NORTH AMERICA: GENE EDITING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 52 EUROPE: GENE EDITING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 53 ASIA PACIFIC: GENE EDITING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 54 LATIN AMERICA: GENE EDITING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 90
8 GENE EDITING MARKET, BY APPLICATION 91
8.1 INTRODUCTION 92
TABLE 55 GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 92
8.2 CELL LINE ENGINEERING 92
8.2.1 INCREASING RESEARCH APPLICATIONS TO PROMOTE MARKET GROWTH 92
TABLE 56 GENE EDITING MARKET FOR CELL LINE ENGINEERING, BY REGION, 2021–2028 (USD MILLION) 93
TABLE 57 NORTH AMERICA: GENE EDITING MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 58 EUROPE: GENE EDITING MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 59 ASIA PACIFIC: GENE EDITING MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 60 LATIN AMERICA: GENE EDITING MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 94
8.3 GENETIC ENGINEERING 94
8.3.1 GROWING USE OF ANIMAL SIMULATION MODELS IN RESEARCH AND INCREASING INTEREST IN GM CROPS TO DRIVE MARKET 94
TABLE 61 GENE EDITING MARKET FOR GENETIC ENGINEERING, BY REGION, 2021–2028 (USD MILLION) 95
TABLE 62 NORTH AMERICA: GENE EDITING MARKET FOR GENETIC ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 63 EUROPE: GENE EDITING MARKET FOR GENETIC ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 64 ASIA PACIFIC: GENE EDITING MARKET FOR GENETIC ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 65 LATIN AMERICA: GENE EDITING MARKET FOR GENETIC ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION) 96
8.4 DRUG DISCOVERY & DEVELOPMENT 97
8.4.1 GROWING RESEARCH AND APPLICATIONS IN DRUG DISCOVERY & DEVELOPMENT TO BOOST GROWTH 97
TABLE 66 GENE EDITING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 67 NORTH AMERICA: GENE EDITING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 68 EUROPE: GENE EDITING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 69 ASIA PACIFIC: GENE EDITING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 70 LATIN AMERICA: GENE EDITING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 99
8.5 OTHER APPLICATIONS 99
TABLE 71 GENE EDITING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 72 NORTH AMERICA: GENE EDITING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 73 EUROPE: GENE EDITING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 74 ASIA PACIFIC: GENE EDITING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 75 LATIN AMERICA: GENE EDITING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 101
9 GENE EDITING MARKET, BY END USER 102
9.1 INTRODUCTION 103
TABLE 76 GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 103
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 103
9.2.1 PHARMA & BIOTECH COMPANIES TO HOLD LARGEST MARKET SHARE 103
TABLE 77 GENE EDITING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 78 NORTH AMERICA: GENE EDITING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 79 EUROPE: GENE EDITING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 80 ASIA PACIFIC: GENE EDITING MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 81 LATIN AMERICA: GENE EDITING MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 105
9.3 ACADEMIC & RESEARCH INSTITUTES 105
9.3.1 TREND OF COLLABORATIVE RESEARCH TO SUPPORT MARKET GROWTH 105
TABLE 82 GENE EDITING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 83 NORTH AMERICA: GENE EDITING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 84 EUROPE: GENE EDITING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 85 ASIA PACIFIC: GENE EDITING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 86 LATIN AMERICA: GENE EDITING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 107
9.4 OTHER END USERS 108
TABLE 87 GENE EDITING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 88 NORTH AMERICA: GENE EDITING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 89 EUROPE: GENE EDITING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 90 ASIA PACIFIC: GENE EDITING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 91 LATIN AMERICA: GENE EDITING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 109

10 GENE EDITING MARKET, BY REGION 110
10.1 INTRODUCTION 111
TABLE 92 GENE EDITING MARKET, BY REGION, 2021–2028 (USD MILLION) 111
10.2 NORTH AMERICA 111
10.2.1 NORTH AMERICA: RECESSION IMPACT 111
FIGURE 26 NORTH AMERICA: GENE EDITING MARKET SNAPSHOT 112
TABLE 93 NORTH AMERICA: GENE EDITING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 94 NORTH AMERICA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 113
TABLE 95 NORTH AMERICA: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 113
TABLE 96 NORTH AMERICA: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 114
TABLE 97 NORTH AMERICA: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 114
10.2.2 US 114
10.2.2.1 Robust investment to drive market growth 114
TABLE 98 US: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 115
TABLE 99 US: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 115
TABLE 100 US: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 115
TABLE 101 US: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 116
10.2.3 CANADA 116
10.2.3.1 Availability of research funding to support growth 116
TABLE 102 CANADA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 116
TABLE 103 CANADA: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 117
TABLE 104 CANADA: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 117
TABLE 105 CANADA: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 117
10.3 EUROPE 118
10.3.1 EUROPE: RECESSION IMPACT 118
TABLE 106 EUROPE: GENE EDITING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 107 EUROPE: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 119
TABLE 108 EUROPE: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 119
TABLE 109 EUROPE: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 119
TABLE 110 EUROPE: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 120
10.3.2 GERMANY 120
10.3.2.1 Strong academic base and rising awareness to boost market 120
TABLE 111 GERMANY: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 120
TABLE 112 GERMANY: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 121
TABLE 113 GERMANY: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 121
TABLE 114 GERMANY: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 121
10.3.3 UK 122
10.3.3.1 Government support to boost market growth 122
TABLE 115 UK: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 122
TABLE 116 UK: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 122
TABLE 117 UK: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 123
TABLE 118 UK: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 123
10.3.4 FRANCE 123
10.3.4.1 Government funding for genomics and rising research investments to propel market 123
TABLE 119 FRANCE: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 124
TABLE 120 FRANCE: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 124
TABLE 121 FRANCE: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124
TABLE 122 FRANCE: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 125
10.3.5 ITALY 125
10.3.5.1 Increasing collaborations to drive genomic medicine research and favor market 125
TABLE 123 ITALY: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 125
TABLE 124 ITALY: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126
TABLE 125 ITALY: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 126
TABLE 126 ITALY: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 126
10.3.6 SPAIN 127
10.3.6.1 Proactive research funding to boost market 127
TABLE 127 SPAIN: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 127
TABLE 128 SPAIN: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 127
TABLE 129 SPAIN: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 128
TABLE 130 SPAIN: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 128
10.3.7 REST OF EUROPE 128
TABLE 131 REST OF EUROPE: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 129
TABLE 132 REST OF EUROPE: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 129
TABLE 133 REST OF EUROPE: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 129
TABLE 134 REST OF EUROPE: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 130
10.4 ASIA PACIFIC 130
10.4.1 ASIA PACIFIC: RECESSION IMPACT 130
FIGURE 27 ASIA PACIFIC: GENE EDITING MARKET SNAPSHOT 131
TABLE 135 ASIA PACIFIC: GENE EDITING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 136 ASIA PACIFIC: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 132
TABLE 137 ASIA PACIFIC: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 132
TABLE 138 ASIA PACIFIC: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 133
TABLE 139 ASIA PACIFIC: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 133
10.4.2 CHINA 133
10.4.2.1 China to hold largest share of APAC market 133
TABLE 140 CHINA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 134
TABLE 141 CHINA: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 134
TABLE 142 CHINA: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 134
TABLE 143 CHINA: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 135
10.4.3 JAPAN 135
10.4.3.1 Focus on cancer research to showcase favorable scenarios for gene editing market 135
TABLE 144 JAPAN: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 135
TABLE 145 JAPAN: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 136
TABLE 146 JAPAN: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 136
TABLE 147 JAPAN: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 136
10.4.4 INDIA 137
10.4.4.1 Growing startups and government support to boost growth potential 137
TABLE 148 INDIA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 137
TABLE 149 INDIA: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 137
TABLE 150 INDIA: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 138
TABLE 151 INDIA: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 138
10.4.5 REST OF ASIA PACIFIC 138
TABLE 152 REST OF ASIA PACIFIC: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 139
TABLE 153 REST OF ASIA PACIFIC: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 139
TABLE 154 REST OF ASIA PACIFIC: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 139
TABLE 155 REST OF ASIA PACIFIC: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 140
10.5 LATIN AMERICA 140
10.5.1 LATIN AMERICA: RECESSION IMPACT 140
TABLE 156 LATIN AMERICA: GENE EDITING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 157 LATIN AMERICA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 141
TABLE 158 LATIN AMERICA: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 141
TABLE 159 LATIN AMERICA: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 142
TABLE 160 LATIN AMERICA: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 142
10.5.2 BRAZIL 142
10.5.2.1 Brazil to dominate Latin American market 142
TABLE 161 BRAZIL: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 143
TABLE 162 BRAZIL: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143
TABLE 163 BRAZIL: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 143
TABLE 164 BRAZIL: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 144
10.5.3 REST OF LATIN AMERICA 144
TABLE 165 REST OF LATIN AMERICA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 144
TABLE 166 REST OF LATIN AMERICA: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 145
TABLE 167 REST OF LATIN AMERICA: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 145
TABLE 168 REST OF LATIN AMERICA: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 145
10.5.4 MIDDLE EAST & AFRICA 146
10.5.4.1 Increasing adoption of genetic testing to propel market 146
10.5.5 MIDDLE EAST & AFRICA: RECESSION IMPACT 146
TABLE 169 MIDDLE EAST & AFRICA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 147
TABLE 170 MIDDLE EAST & AFRICA: GENE EDITING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 147
TABLE 171 MIDDLE EAST & AFRICA: GENE EDITING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 147
TABLE 172 MIDDLE EAST & AFRICA: GENE EDITING MARKET, BY END USER, 2021–2028 (USD MILLION) 148
11 COMPETITIVE LANDSCAPE 149
11.1 OVERVIEW 149
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 150
FIGURE 28 KEY PLAYER STRATEGIES, 2020–2023 150
11.3 MARKET SHARE ANALYSIS 151
TABLE 173 GENE EDITING MARKET: DEGREE OF COMPETITION 151
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 152
FIGURE 30 REVENUE ANALYSIS OF TOP FOUR MARKET PLAYERS (2020–2022) 152
11.5 COMPANY EVALUATION QUADRANT, 2022 153
11.5.1 STARS 153
11.5.2 EMERGING LEADERS 153
11.5.3 PERVASIVE PLAYERS 153
11.5.4 EMERGING COMPANIES 153
FIGURE 31 GENE EDITING MARKET: COMPANY EVALUATION QUADRANT, 2022 154
11.6 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022 155
11.6.1 PROGRESSIVE COMPANIES 155
11.6.2 STARTING BLOCKS 155
11.6.3 RESPONSIVE COMPANIES 155
11.6.4 DYNAMIC COMPANIES 155
FIGURE 32 GENE EDITING MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022 156
11.7 COMPANY FOOTPRINT ANALYSIS 157
11.7.1 PRODUCT/SERVICE FOOTPRINT ANALYSIS 157
TABLE 174 PRODUCT/SERVICE FOOTPRINT ANALYSIS: GENE EDITING MARKET (2022) 157
11.7.2 GEOGRAPHIC FOOTPRINT ANALYSIS 158
TABLE 175 GEOGRAPHIC FOOTPRINT ANALYSIS: GENE EDITING MARKET (2022) 158
11.8 COMPETITIVE SCENARIO 159
12 COMPANY PROFILES 161
12.1 KEY COMPANIES 161
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 THERMO FISHER SCIENTIFIC 161
TABLE 176 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 161
FIGURE 33 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2022) 162
12.1.2 MERCK KGAA 165
TABLE 177 MERCK KGAA: BUSINESS OVERVIEW 165
FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2022) 166
12.1.3 GENSCRIPT 169
TABLE 178 GENSCRIPT: BUSINESS OVERVIEW 169
FIGURE 35 GENSCRIPT: COMPANY SNAPSHOT (2022) 170
12.1.4 AGILENT TECHNOLOGIES 173
TABLE 179 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW 173
FIGURE 36 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2022) 174
12.1.5 PERKINELMER 176
TABLE 180 PERKINELMER: BUSINESS OVERVIEW 176
FIGURE 37 PERKINELMER: COMPANY SNAPSHOT (2022) 177
12.1.6 LONZA 180
TABLE 181 LONZA: BUSINESS OVERVIEW 180
FIGURE 38 LONZA: COMPANY SNAPSHOT (2022) 181
12.1.7 TECAN LIFE SCIENCES 183
TABLE 182 TECAN LIFESCIENCES: BUSINESS OVERVIEW 183
FIGURE 39 TECAN LIFESCIENCES: COMPANY SNAPSHOT (2022) 184
12.1.8 SANGAMO THERAPEUTICS 186
TABLE 183 SANGAMO THERAPEUTICS: BUSINESS OVERVIEW 186
FIGURE 40 SANGAMO THERAPEUTICS: COMPANY SNAPSHOT (2022) 186
12.1.9 EDITAS MEDICINE 188
TABLE 184 EDITAS MEDICINE: BUSINESS OVERVIEW 188
FIGURE 41 EDITAS MEDICINE: COMPANY SNAPSHOT (2022) 188
12.1.10 CRISPR THERAPEUTICS AG 190
TABLE 185 CRISPR THERAPEUTICS AG: BUSINESS OVERVIEW 190
FIGURE 42 CRISPR THERAPEUTICS AG: COMPANY SNAPSHOT (2022) 190
12.1.11 PRECISION BIOSCIENCES 192
TABLE 186 PRECISION BIOSCIENCES: BUSINESS OVERVIEW 192
FIGURE 43 PRECISION BIOSCIENCES: COMPANY SNAPSHOT (2020) 192
12.1.12 CELLECTIS S.A. 194
TABLE 187 CELLECTIS: BUSINESS OVERVIEW 194
FIGURE 44 CELLECTIS: COMPANY SNAPSHOT (2022) 194
12.1.13 INTELLIA THERAPEUTICS 196
TABLE 188 INTELLIA THERAPEUTICS: BUSINESS OVERVIEW 196
FIGURE 45 INTELLIA THERAPEUTICS: COMPANY SNAPSHOT (2022) 196
12.1.14 BLUEBIRD BIO INC. 198
TABLE 189 BLUEBIRD BIO: BUSINESS OVERVIEW 198
FIGURE 46 BLUEBIRD BIO: COMPANY SNAPSHOT (2022) 198
12.1.15 REGENERON PHARMACEUTICALS INC. 200
TABLE 190 REGENERON PHARMACEUTICALS: BUSINESS OVERVIEW 200
FIGURE 47 REGENERON PHARMACEUTICALS: COMPANY SNAPSHOT (2022) 200
12.1.16 AMSBIO 202
TABLE 191 AMSBIO: BUSINESS OVERVIEW 202
12.1.17 CREATIVE BIOGENE 203
TABLE 192 CREATIVE BIOGENE: BUSINESS OVERVIEW 203
12.1.18 SYNTHEGO CORPORATION 204
TABLE 193 SYNTHEGO CORPORATION: BUSINESS OVERVIEW 204
12.1.19 BEAM THERAPEUTICS 206
TABLE 194 BEAM THERAPEUTICS: BUSINESS OVERVIEW 206
FIGURE 48 BEAM THERAPEUTICS: COMPANY SNAPSHOT (2022) 206
12.2 OTHER PLAYERS 207
12.2.1 CARIBOU BIOSCIENCES 207
12.2.2 ORIGENE TECHNOLOGIES 207
12.2.3 NEW ENGLAND BIOLABS 208
12.2.4 INSCRIPTA 208
12.2.5 MAMMOTH BIOSCIENCES 209
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 210
13.1 DISCUSSION GUIDE 210
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 213
13.3 CUSTOMIZATION OPTIONS 215
13.4 RELATED REPORTS 215
13.5 AUTHOR DETAILS 216

ページTOPに戻る

Table of Contents

Summary

The gene editing market is projected to grow from USD 5.3 billion in 2023 to USD 10.6 billion by 2028 at a CAGR of 15.0%. Rising government funding and number of genomics projects has emerged as a high impact driver for the market. In March 2022, the US National Institutes of Health (NIH) expanded its funding for gene editing research, allocating USD 89 million for additional projects. Similarly, the European Union launched the Horizon 2020 program, providing substantial financial resources to promote genomics research and gene editing projects. Moreover, several countries, including China, Japan, and South Korea, have established national genomics programs and dedicated funding to drive advancements in gene editing technologies.

“Gene editing services to witness the highest growth during the forecast period.”
Based on product & service, the gene editing market is segmented into reagents & consumables, software & systems, and services. The gene editing services market includes sequencing services; data analysis; bioinformatics services; and other services, such as informatics, cleanup, gene expression, and DNA synthesis services. Additionally, service providers also offer customized sequencing services. The introduction of sequencing services in biomedical applications is expected to boost the demand for genomic sequencing, subsequently boosting the gene editing market.
“Pharmaceutical & biotechnology companies accounted for the largest share of the global gene editing market in 2022.”
Based on end users, the gene editing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. Other end users include diagnostic companies, CROs, and CDMOs. High demand for gene editing in pharma applications such as pharmacogenomics has contributed to the dominance of this segment throughout the forecast period. The growing importance of biomarkers is expected to drive the use of genomic systems and services in this segment, owing to the various applications of biomarkers in drug development. With this, biotechnology companies are also building genomic databases to discover and develop new therapeutics.

“Asia Pacific is estimated to register the highest CAGR during the forecast period.”
The gene editing market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America, and the Middle East & Africa (MEA). The Asia Pacific region is expected to be the fastest-growing market for gene editing due to the increasing investments in research and the rising applications of gene synthesis for the genetic engineering of cells and tissues of organisms. Cancer has become one of the leading causes of death in Japan, prompting the government to undertake various initiatives to reduce its prevalence and mortality. For example, the Agency for Medical Research and Development has undertaken many research projects, including the Japan Regenerative Medicine Project, Japan Genomic Medicine Project, and Japan Cancer Research Project. The market in Japan has also witnessed various collaborations and partnerships between local organizations and leading global players seeking to introduce and offer technologically advanced products and services in the country.
Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Respondent: Supply Side (70%) , Demand side (30%)
• By Designation: C-level (55%), Director-level (20%), and Others (25%)
• By Region: North America (50%), Europe (20%), AsiaPacific (20%), and Rest of the World(10%)

List of Companies Profiled in the Report
• Merck KGaA (Germany)
• Thermo Fisher Scientific, Inc. (US)
• GenScript (China)
• Agilent Technologies (US)
• PerkinElmer (US)
• Lonza (Switzerland)
• Tecan Life Sciences (Switzerland)
• Sangamo Therapeutics (US)
• Editas Medicine (US)
• CRISPR Therapeutics AG (Switzerland)
• Precision Biosciences (US)
• Cellectis S.A. (France)
• Intellia Therapeutics (US)
• Bluebird Bio, Inc. (US)
• Regeneron Pharmaceuticals (US)
• AMSBIO (England)
• Creative Biogene (US)
• Synthego Corporation (US)
• Beam Therapeutics Inc. (US)
• Caribou Biosciences, Inc. (US)
• OriGene Technologies (US)
• New England Biolabs (US)
• Inscripta (US)
• Mammoth Biosciences (US).

Research Coverage
This report studies the gene editing market based on product & service, technology, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total gene editing market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on gene editing offered by the top 25 players in the market. The report analyzes the gene editing market by product & service, technology, application, end user, and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various products/services/technologies across key geographic regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the gene editing market
• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the gene editing market

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（gene）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（gene）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?